Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Janz, Martin Dr. (4) Kammertöns, Thomas Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (1) Lusatis, Simone (1) Mathas, Stephan Dr. (5) Pezzutto, Antonio Prof. Dr. (3) Scheidereit, Claus Prof. Dr. (1) Selbach, Matthias Prof. Dr. (4) Uckert, Wolfgang Prof. Dr. (1) Walther, Wolfgang Prof. Dr. (1) Willimsky, Gerald Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (20) (-) Wollert-Wulf, Brigitte (2) (-) Biologie maligner Lymphome (2) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (20) Translationale Onkologie solider Tumore (1) 1992 (4) 1993 (7) 1994 (5) (-) 1995 (8) 1996 (6) (-) 1997 (9) 1998 (9) (-) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) (-) 2006 (3) 2007 (5) 2008 (5) 2009 (2) 2010 (7) 2011 (5) 2012 (6) 2013 (13) 2014 (4) 2015 (4) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (7) 2024 (1) 22 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Wollert-Wulf, BrigitteBiologie maligner LymphomeMolekulare Immunologie und Gentherapie 1995199719992006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. März 1999 / J Exp Med T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice T. Schueler Z. Qin S. Ibe N. Noben-Trauth T. Blankenstein 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 01. Januar 1995 / Cytokine The rat interleukin-4 receptor: coevolution of ligand and receptor G. Richter G. Hein T. Blankenstein T. Diamantstein 01. Januar 1995 / Blood Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice Z. Qin L.J.H. van Tits W.A. Buurman T. Blankenstein 01. Januar 1995 / J Immunol IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression F. Salazar-Onfray M. Petersson L. Franksson M. Matsuda T. Blankenstein K. Karre R. Kiessling 01. Januar 1997 / Eur J Immunol Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency S. Cayeux G. Richter C. Becker C. Beck A. Aicher A. Pezzutto B. Doerken T. Blankenstein 01. Januar 1997 / J Immunol Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation S. Cayeux G. Richter G. Noffz B. Doerken T. Blankenstein 01. Januar 1997 / Gene Ther Loss of retroviral gene expression in bone marrow reconstituted mice correlates with down regulation of gene expression in long term culture initiating cells C. Lange T. Blankenstein 01. Januar 1997 / Hum Gene Ther Transient expression of SV 40 large T antigen by Cre/LoxP mediated site specific deletion in primary human tumor cells L.P. Li P.M. Schlag T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
01. März 1999 / J Exp Med T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice T. Schueler Z. Qin S. Ibe N. Noben-Trauth T. Blankenstein
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
01. Januar 1995 / Cytokine The rat interleukin-4 receptor: coevolution of ligand and receptor G. Richter G. Hein T. Blankenstein T. Diamantstein
01. Januar 1995 / Blood Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice Z. Qin L.J.H. van Tits W.A. Buurman T. Blankenstein
01. Januar 1995 / J Immunol IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression F. Salazar-Onfray M. Petersson L. Franksson M. Matsuda T. Blankenstein K. Karre R. Kiessling
01. Januar 1997 / Eur J Immunol Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency S. Cayeux G. Richter C. Becker C. Beck A. Aicher A. Pezzutto B. Doerken T. Blankenstein
01. Januar 1997 / J Immunol Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation S. Cayeux G. Richter G. Noffz B. Doerken T. Blankenstein
01. Januar 1997 / Gene Ther Loss of retroviral gene expression in bone marrow reconstituted mice correlates with down regulation of gene expression in long term culture initiating cells C. Lange T. Blankenstein
01. Januar 1997 / Hum Gene Ther Transient expression of SV 40 large T antigen by Cre/LoxP mediated site specific deletion in primary human tumor cells L.P. Li P.M. Schlag T. Blankenstein